title: Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma--a phase II trial.
authors.affiliation: Department of Haematology, Derriford Hospital, Plymouth, UK. michelle.furtado@nhs.net.
authors.forename: Michelle
authors.initials: M
authors.lastname: Furtado
authors.forename: Martin J S
authors.initials: MJ
authors.lastname: Dyer
authors.forename: Rod
authors.initials: R
authors.lastname: Johnson
authors.forename: Margie
authors.initials: M
authors.lastname: Berrow
authors.forename: Simon
authors.initials: S
authors.lastname: Rule
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; D000970:Antineoplastic Agents; C527517:ofatumumab
keywords: CD20 antibody; mantle cell lymphoma; ofatumumab